Blood test may help doctors switch cancer treatment earlier

NCT ID NCT05826964

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a blood test that tracks tumor DNA (ctDNA) can help doctors switch treatments earlier in people with metastatic breast cancer. The goal is to see if acting on a molecular signal of progression, before symptoms or scans show it, can keep the cancer under control longer. About 24 participants will be randomly assigned to switch therapy early based on ctDNA levels or wait for standard signs of progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Aromatase inhibitor (AI) or selective estrogen receptor degrader (SERD) plus a CDK4/6 inhibitor

What this could lead to

If successful, this could show that using a blood test to detect early molecular changes allows doctors to switch treatments sooner, potentially keeping metastatic breast cancer under control for longer.

What could go wrong

This is a small, early-phase study (24 people) testing a monitoring strategy, not a new drug. The approach may not improve outcomes or could lead to unnecessary treatment switches.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm estrogen-receptor positive breast cancer Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Miami

    Miami, Florida, 33136, United States